Make Informed Investment Decisions with Affordable Access to Experts
Exploring the market potential of FT218 (Avadel’s micropump sodium oxybate) in treating narcolepsy compared to existing therapiesTicker(s): AVDL, JAZZ
Name: Dr Andrew Westwood - MD
Institution: Columbia University Medical Center
- Assistant Professor of Neurology at CUMC with a Full-time clinical sleep practice in the Division of Epilepsy and the Sleep Disorders Center in the Department of Neurology.
- Treats about 30 patients with narcolepsy, in addition to idiopathic hypersomnia and residual sleepiness in OSA.
- Board Certified in Sleep Medicine and Neurology.
Please describe your clinical practice. How many patients with narcolepsy do you currently treat?Added By: c_admin
Can you give us your thoughts on the trial design for FT218.Added By: c_admin
How much of advantage is the one single dose before bedtime formulation of Avadel's micropump sodium oxybate? If approved, how likely would you be to switch patients to this drug?Added By: c_admin
How well tolerated is JZP-110? What % of patient population would not be prescribed the drug due to side effects?Added By: c_admin
How important do you find the lower levels of sodium in JZP-110? What % of your patient population is affected by the sodium content in traditional therapies? Do you see lower sodium as being a benefit?Added By: c_admin
On a scale from 1-10, 10 being extremely excited where would you put your level of excitement for FT218?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.